Hospital

Datopotamab deruxtecan is an investigational TROP2 directed antibody drug conjugate that showed positive survival impact compared to chemotherapy.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

However, increasing dietary niacin did not reduce risk of mortality from cardiovascular disease, the primary cause of death associated with nonalcoholic fatty liver disease.

Living organisms rely on iron for survival and replication. Can new research discoveries disrupt C. difficile’s ability to maintain iron homeostasis?

Targeted use of ultraviolet light and sporicidal treatment can reduce disease transmission alongside existing interventions.

Cardioprotective antihyperglycemic agents are underutilized for inpatient care in heart failure patients. Lack of use can lead to preventable patient deaths and hospital readmissions.

The pharmacist’s role may vary across different practices and institutions.

This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

Sustained cognitive improvement is likely a result of lower inflammation, remission of comorbidities, higher physical activity, and better mood.

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

The authors emphasize that further research on a diverse population that focuses on the role of duration and lifestyle choices and neuroinflammatory markers should be performed.

Nutrition is foundational to health, but healthy eating does not look the same for everyone.

The researchers made a connection between positive outcomes for infectious disease patients, higher reimbursement class, and the presence of pharmacists in care teams.

The approval of irinotecan liposome offers an improved first-line treatment option for individuals diagnosed with metastatic pancreatic adenocarcinoma.

Iloprost had also received Priority Review and Orphan Drug Designations for this indication, and FDA approval in 2004 for the treatment of pulmonary arterial hypertension.

Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.

In a projective model, tirzepatide saved patients more than $15,000 per quality-adjusted life-year.

This accreditation allows pharmacists to give diabetes education to patients with Medicare and receive Medicare reimbursement.

Progression-free survival in the ixazomib/pegylated liposomal doxorubicin/dexamethasone group was shorter than in the ixazomib/lenalidomide/dexamethasone group.

The results indicate promising rates of complete response, manageable adverse events, and dose-dependent exposure in both dose groups.

Mouthwash that contains chlorhexidine gluconate was especially effective at improving hyperglycemic status in younger patients with diabetes.

Cardiac Solutions, a physician-owned practice specializing in personalized treatment plans, used RevUp Remote Patient Monitoring and Chronic Care Management to achieve these cardiovascular readmission rates.

If approved, this would mark the first MDMA-assisted therapy and psychedelic-assisted therapy approved, calling for a reschedule of MDMA from Schedule I. A PDUFA was set for this summer.

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses how established quality standards, drawing from the realm of small molecule drugs and evolving to meet the complexities of biologics, play a pivotal role in fostering trust.

The updated indication for the respiratory syncytial virus vaccine is for adults aged 50 to 59 with underlying conditions who are at an increased risk of contracting the virus.

The vitamin improved lipid metabolism to slow the progression of the disease.

Bepirovirsen is a triple action investigational antisense oligonucleotide and is being evaluated in the B-Well phase 3 clinical trial program for the treatment of chronic hepatitis B.

In addition to improved progression-free survival, patients treated with this regimen also showed improved complete response or stronger and were minimal residual disease-negative.

Fouad Atouf, senior vice president of global biologics at US Pharmacopeia, discusses the importance of robust quality standards in addressing concerns regarding biosimilar safety and efficacy.